Stockreport

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies Incorporated  (OSTX) 
PDF Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: [Read more]